Abstract: The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(?) (GPIb(?) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(?), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(?) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.

Abstract: The invention relates to a method for obtaining an image of ischemic, infarcted or necrotic tissue in a subject, comprising the step of administering an imaging agent comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound. For example, the invention concerns to the use of phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives, and more specifically hypericin or its derivatives, as necrosis or infarct specific agents. The phenanthro[1,10,9,8-opqra]perylene-7,14-dione derivatives can be labeled with a radionuclide, a radiopaque material or a material enhancing the effects magnetic resonance imaging. The invention further features a pharmaceutical composition comprising a phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound optionally conjugated to a radionuclide or a radiopaque material, provided that said phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound is not mono-[123I]-iodohypericin.

Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.

Abstract: The invention provides a process of making porous structures or materials, including the colloidal processing (e.g. slip casting, pressure casting, tape casting or electrophoretic deposition) of solid particle emulsions to form a green body that can be directly sintered without a de-binding step.

Abstract: The present invention relates to pharmaceutical compositions for the treatment of prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A), wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections.

Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).

Abstract: The present invention relates to the use of N-aminoimidazole or N-aminoimidazole-thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.

Abstract: This invention consists of a modified gluten biopolymer for use in industrial applications, such as composites and foams. In the present work, the fracture toughness of the gluten polymer was improved with the addition of a thiol-containing modifying agent. This work also resulted in the development of a gluten biopolymer-modified fiber bundle, demonstrating the potential to process fully biodegradable composite materials. Qualitative analysis suggests that a reasonably strong interface between the natural fibers and biopolymer matrix can form spontaneously under the proper conditions. Therefore this invention relates to a modified gluten biopolymer for use in industrial applications, such as composites, stabilized foams and molded articles of manufactures. The present invention relates to a new gluten based biopolymer with modified properties, such as an increase in impact strength, and prepared by using thiol-containing molecules.

Abstract: The present invention provides integrase interacting proteins including cofactors which promote strand transfer activity of viral integrase, more particularly HIV integrase, and methods and uses relating thereto. The present invention also relates to methods of identifying molecules interacting with integrase interacting protein and their use as an antiviral.

Abstract: Present invention is a system of blood glucose monitoring and intensive insulin therapy in a ICU for strict maintenance of normoglycemia which reduces intensive care and hospital mortality and morbidity of critically ill adult patients. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established. The invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity). This automated insulin monitoring systems significantly reduces the workload and human resource management problems for intensive insulin therapy in patients in the ICU.

Abstract: A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.

Abstract: Laser interferometers and high-quality linear encoders both are competitive linear measurement systems used in high-precision machines. Plane laser interferometry allows measuring to a target that moves perpendicular to the measurement direction and to set up the laser beam in line with the functional point. In this way, a stacking of measurement systems can be avoided and a measurement configuration complying with the Abbe principle can be configured. On the other hand, laser interferometry is known to be sensitive to environmental changes. High-quality linear scales are used as an alternative. A disadvantage of linear scales is that the target is only allowed to move along the measurement axis. For targets translating in more than one direction with a range over several millimeters, this leads to a simple stacking of several linear scales together with the supporting slides. This indirect way of measuring introduces errors and partially destroys the accuracy provided by modern linear scales.

Abstract: The destruction of chlorinated hydrocarbons, such as carbon tetrachloride, over lanthanide-based solid catalysts in the presence of steam has been investigated between 200 and 350° C. Ln2O3/AL2O3 (e.g. Ln=La, Nd, Ce and Pr) show a very high catalytic hydrolysis activity. The destruction capacity gradually increases with increasing temperature and reaches a maximum value of 42.3·106 ppm.h?1 at 350° C. for a 10 wt % Ln2O3/AL2O3 catalyst This destruction capacity could be maintained for a least 48 hours. The catalyst activity is also function of the type of lanthanide oxide; i.e., La?Nd>Ce?Pr. The process is based on a delicate equilibrium between destructive adsorption of CCI4 onto the lanthanide oxide and the dechlorination of the formed lanthanide chloride with steam. Steam being responsible for the in situ regeneration of the catalytic active phase.

Abstract: The present invention provides novel inhibitors of angiogenesis. The invention relates to PF4var1 and fragments and modifications thereof with anti-angiogenic activity. Therefore, the present invention relates to the use of said proteins and peptides as a medicine, more in particular for the treatment or prevention of angiogenesis or for the manufacture of a medicament for the prevention or treatment of angiogenic diseases. The invention also provides pharmaceutical compositions comprising said proteins and peptides and method of preventing or treating angiogenic disorders.

Abstract: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections.

Abstract: The essence of the invention is the use of supercooled superconductors for generation of high-frequency electric oscillations. The superconductor is supercooled, i.e. in the normal phase at a temperature lower than the critical transition temperature for superconductivity, under an applied electric energy source. In such non equilibrium conditions the superconductor can have negative differential conductivity which can be used as an active medium in generators of electric (current and voltage) oscillations. Such generators can be used in the superconducing electronics. Oscillation can be modulated by the change of bias voltage, electrostatic doping by a gate electrode, or by light. When small amplitude oscillations are stabilized near to the critical temperature the generator can be used as a bolometer. The supercooled superconductors can be used also as transistors and frequency mixers. The negative differential conductivity of superconductor is created by the excess conductivity of fluctuation Cooper pairs.

Abstract: The present invention relates to the use of modified nucleotides and single or double stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl and O-substituted or O-alkylated ribo-cyclohexenyl nucleotides. The present invention also relates to novel modified nucleosides or nucleotides and to the use of the novel modified nucleosides and nucleotides in single or double stranded oligonucleotides for RNA interference, antisense therapy or other applications.

Abstract: A half closed thermoplastic folded honeycomb structure is described which is produced from a continuous web of material by plastic deformation perpendicular to the plane of the material to thereby form half-hexagonal cell walls and small connecting areas. By folding in the direction of conveyance the cell walls meet to thereby form the honeycomb structure.

Abstract: The invention provides a process of making porous structures or materials, including the colloidal processing (e.g. slip casting, pressure casting, tape casting or electrophoretic deposition) of solid particle emulsions to form a green body that can be directly sintered without a de-binding step.

Abstract: A system and method for pre-operatively obtaining a prediction of a post-operative image of at least part of a body is disclosed. A 3D pre-operative description is determined of at least part of a body, and a pre-operative 2D photograph is acquired of the at least part of the body from any viewing position. The 3D pre-operative description is matched with the pre-operative 2D photograph, and a deformation field is determined for deforming the 3D pre-operative description. A predicted post-operative image of a 3D post-operative description of the at least part of the body is derived by means of the deformation field and the pre-operative 2D photograph.